Autopsy report · NCT03630055

Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion

“Assessment for futility”

The sponsor’s own words in the registry.

Life of this trial

• Registered 2 months before it started.
• Ran for about 6 years 9 months before it stopped.
• 930 participants enrolled.
• No results are posted on the registry.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Ottawa Heart Institute Research Corporation

Sponsor type

University, hospital or other

Conditions

Radial Artery Occlusion

Interventions

Rivaroxaban 15 MG Oral Tablet [Xarelto]

Participants

930

Sites

3

Countries

Canada, United States

Trials that died the same way

• Perioperative Treprostinil in Pediatric Patients Undergoing the Fontan Operation
  “Interim futility analysis” (79% match in meaning)
• Effects of Hypothermia Upon Outcomes After Acute Traumatic Brain Injury
  “Futility” (79% match in meaning)
• Study of M5049 in DM and PM Participants (NEPTUNIA)
  “Based on interim analyses for futility” (78% match in meaning)
• Efficacy and Safety Study of DP-b99 in Treating Acute Ischemic Stroke
  “The result of a pre-planned interim futility analysis” (77% match in meaning)
• Interest of Intravitreal Injections of Anti-VEGF as Initial and Adjuvant Treatment in Coats Disease
  “Study futility based on the interim analysis” (72% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.